N/A N=20 Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK)
Solid Neoplasms With NTRK Fusions
Primary: Duration of Response (DoR) — 24.5 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=22 Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc
Neoplasm Metastasis
Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants
Phase 2 N=33 A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors
Brain Neoplasms
Primary: Establish a Safe Dose for Oral 5-ALA Administration — 0; 0; 0; 0 Dose Limiting Toxicity
Phase 2 N=77 Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Peripheral T Cell Lymphoma · PTCL · Extranodal NK/T-cell Lymphoma
Primary: Overall Response Rate (ORR) — 31.8; 20.5; 45.5 Percentage of participants
Phase 2 N=30 Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
Blasts 10 Percent or More of Bone Marrow Nucleated Cells · Chronic Myelomonocytic Leukemia-2 · High Grade Malignant Neoplasm
Primary: Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Enrollment and Incidence of Early Transplant — 9; 21 Participants
N/A N=62 Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
Malignant Brain Tumors
Primary: Number of Participants With Objective Response — 2; 2; 4; 19 Participants
Phase 1 N=15 [F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors
Cancer · Brain Tumors
Primary: Area Under the Receiver Operating Curve (ROC AUC) Values for PET Imaging Techniques — 0.98; 0.91; 0.89; 0.82 Probability
N/A N=30 Cerebral Blood Flow During Propofol Anaesthesia
Gastrointestinal Neoplasms
Primary: Changes in Internal Carotid Artery Blood Flow by Treatment of Anaesthesia-induced Hypotension — 27 ml/min — p=0.0276
N/A N=45 ARFI, VisR and DDAI Ultrasound for Improving Discrimination of Malignant and Unresponsive Breast Cancer
Breast Cancer
Primary: Correlation of Peak Displacement (PD) for Detecting Malignancy — 4.5803; 8.628 microns — p=0.2988
Phase 2 N=57 Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Glioblastoma · Gliosarcoma
Primary: 6 Month Progression-free Survival — .438; .292 proportion of participants
Phase 2 N=2 Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
Malignant Peritoneal Mesothelioma
Primary: Objective Response Rate
Phase 2 N=7 Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Astrocytoma, Grades II, III and IV · Glioblastoma Multiforme · Giant Cell Glioblastoma
Primary: Number of Participants With the Presence of Drug in the Tumor Tissue — 2 Participants
Phase 1 N=21 Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
Glioblastoma
Primary: Increase of Interferon Gamma Levels — 0 Participants
N/A N=22 Transcranial Magnetic Stimulation for BECTS
Benign Epilepsy With Centrotemporal Spikes · Language Problems · Learning Disorders
Primary: Interictal Epileptiform Discharge (IED) Frequency — 0; 0; 0; 0 IEDs per 5 minutes — p=0.04